Integrating PNPLA3 into clinical risk prediction
Liver International · 2025-03 · 45 (3)
DOI: 10.1111/liv.16103 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Liver International, online erschienen am 16.09.2024. Verfasst von Vincent L Chen und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology and Hepatology, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, Michigan, USA. Hauptthemen laut MEDLINE: Lipase, Membrane Proteins, Fatty Liver, Non-alcoholic Fatty Liver Disease. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
The PNPLA3 ‐rs738409‐G variant was the first common variant associated with hepatic fat accumulation and progression of metabolic dysfunction‐associated steatotic liver disease (MASLD). Nevertheless, to date, the clinical translation of this discovery has been minimal because it has not yet been clearly demonstrated where the genetic information may play an independent and additional role in clinical risk prediction. In this mini‐review, we will discuss the most relevant evidence regarding the potential integration of the PNPLA3 variant into scores and algorithms for liver disease diagnostics and risk stratification, specifically focusing on MASLD but also extending to liver diseases of other etiologies. The PNPLA3 variant adds little in diagnosing the current state of the disease, whether in terms of presence/absence of metabolic dysfunction‐associated steatohepatitis or the stage of fibrosis. While it can play an important role in prediction, allowing for the early definition of risk profiles that enable tailored monitoring and interventions over time, this is most valuable when applied to populations with relatively high pre‐test probability of having significant fibrosis based on either non‐invasive tests (e.g. Fibrosis‐4) or demographics (e.g. diabetes). Indeed, in this context, integrating FIB4 with the PNPLA3 genotype can refine risk stratification, though there is still no evidence that genetic information adds to liver stiffness determined by elastography. Similarly, in patients with known liver cirrhosis, knowing the PNPLA3 genotype can play a role in predicting the risk of hepatocellular carcinoma, while more doubts remain about the risk of decompensation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Gastroenterology and Hepatology, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, Michigan, USA.
- Research Unit of Hepatology, Università Campus Bio-Medico di Rome, Rome, Italy.
- Hepatology and Clinical Medicine Unit, Fondazione Policlinico Universitario Campus-Biomedico di Roma, Rome, Italy.
ORCID-Profile: Vincent L Chen, Umberto Vespasiani-Gentilucci
Zitieren
APA
Chen, V. L., & Vespasiani-Gentilucci, U. (2025). Integrating PNPLA3 into clinical risk prediction. Liver International, 45(3). https://doi.org/10.1111/liv.16103
Vancouver
Chen VL, Vespasiani-Gentilucci U. Integrating PNPLA3 into clinical risk prediction. Liver International. 2025;45(3). doi:10.1111/liv.16103
BibTeX
@article{Chen2025,
author = {Chen, Vincent L and Vespasiani-Gentilucci, Umberto},
title = {Integrating PNPLA3 into clinical risk prediction},
journal = {Liver International},
year = {2025},
volume = {45},
number = {3},
doi = {10.1111/liv.16103}
}
EUVIMED